- US11976073utility2024Bicyclic Amines as CDK2 Inhibitors0 cites
- US11957661utility2024JAK1 Pathway Inhibitors for the Treatment of Vitiligo0 cites
- US11958861utility2024Spirocyclic Lactams as JAK2 V617F Inhibitors0 cites
- US11952367utility2024Pyridine and Pyridimine Compounds as Pi3k-gamma Inhibitors0 cites
- US11939331utility2024Tricyclic Heterocycles as FGFR Inhibitors0 cites
- US11939328utility2024Quinoline Compounds as Inhibitors of KRAS0 cites
- US11926616utility2024Aminopyrazine Diol Compounds as Pi3k-γ Inhibitors0 cites
- US11926630utility2024Tertiary Alcohols as Pi3k-γ Inhibitors0 cites
- US11918585utility2024Formulations of an AXL/MER Inhibitor0 cites
- US11918581utility2024Combination Therapy Comprising JAK Pathway Inhibitor and Rock Inhibitor0 cites
- US11919904utility2024Sulfonylamide Compounds as CDK2 Inhibitors0 cites
- US11919908utility2024Substituted Pyrrolo[2,3-d]pyrimidine Compounds as JAK2 V617F Inhibitors0 cites
- US11912722utility2024Tricyclic Heteroaryl Compounds as Sting Activators0 cites
- US11905292utility2024Process and Intermediates for Preparing a JAK Inhibitor0 cites
- US11897889utility2024Process and Intermediates for Preparing a JAK1 Inhibitor0 cites
- US11896595utility2024JAK1 Pathway Inhibitors for the Treatment of Chronic Lung Allograft Dysfunction0 cites
- US11896717utility2024Sustained-release Dosage Forms of Ruxolitinib0 cites
- US11897891utility2024Tricyclic Heterocycles as FGFR Inhibitors0 cites
- US11891388utility2024Pyrazolopyridine Compounds and Uses Thereof0 cites
- US11884665utility2024Pyrazolopyridines and Triazolopyridines as A2A / A2B Inhibitors0 cites